Drugs · acquisition-cost intelligence
Tobramycin
· ingredient tobramycinAntibiotics· TOBRAMYCIN 3 mg/mL
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per ML
$1.02
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per ML — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other tobramycin products, cheapest acquisition cost first. Per ML — confirm strength/form equivalence before switching.
| Product | NADAC / ML | vs this |
|---|---|---|
| Tobramycin | $0.64108 | −$0.37630 |
| Tobramycin | $0.64108 | −$0.37630 |
| Kitabis Pak | $1.08 | +$0.06480 |
| tobramycin and dexamethasone | $4.96 | +$3.95 |
| Tobradex ST | $46.67 | +$45.66 |
| Zylet | $64.48 | +$63.46 |
Medicare Part D coverage · CY2026
On 328 plan formularies · typical tier 1
Prior auth 0% · Step therapy 0% · Quantity limit 19% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.